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Acute kidney injury may increase the risk for chronic kidney
disease and end-stage renal disease. In an attempt to
summarize the literature and provide more compelling
evidence, we conducted a systematic review comparing the
risk for CKD, ESRD, and death in patients with and without
AKI. From electronic databases, web search engines, and
bibliographies, 13 cohort studies were selected, evaluating
long-term renal outcomes and non-renal outcomes in
patients with AKI. The pooled incidence of CKD and ESRD
were 25.8 per 100 person-years and 8.6 per 100 person-years,
respectively. Patients with AKI had higher risks for
developing CKD (pooled adjusted hazard ratio 8.8, 95% CI
3.1–25.5), ESRD (pooled adjusted HR 3.1, 95% CI 1.9–5.0), and
mortality (pooled adjusted HR 2.0, 95% CI 1.3–3.1) compared
with patients without AKI. The relationship between AKI and
CKD or ESRD was graded on the basis of the severity of AKI,
and the effect size was dampened by decreased baseline
glomerular filtration rate. Data were limited, but AKI was also
independently associated with the risk for cardiovascular
disease and congestive heart failure, but not with
hospitalization for stroke or all-cause hospitalizations.
Meta-regression did not identify any study-level factors that
were associated with the risk for CKD or ESRD. Our review
identifies AKI as an independent risk factor for CKD, ESRD,
death, and other important non-renal outcomes.
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The incidence of acute kidney injury (AKI) has been
increasing over time.1,2 Concurrently, the prevalence of
chronic kidney disease (CKD) has also been increasing.3
AKI has long been thought of as a completely reversible
syndrome. However, over the past several years, a plethora of
data from experimental animals and humans have been
published that indicate that AKI more than likely results in
permanent kidney damage (i.e., CKD) and may also result in
damage to non-renal organs.4,5
Moreover, the proportion of patients surviving after AKI
has also been increasing over time.1,6–8 Thus, if AKI indeed
heightens the risk for CKD and other organ damage, then it
could imply significant public health concerns with regard to
the absolute number of persons developing incident CKD,
progressive CKD, end-stage renal disease (ESRD), and
cardiovascular events.
Non-contemporary long-term follow-up studies of AKI
were plagued by a lack of follow-up of non-AKI patients,
as a result of which the relative risk or hazard ratio (HR)
for the outcome of CKD in those with vs. those without
AKI could not be calculated.9 However, over the past few
years, several studies have attempted to estimate the
incidence rate and relative hazards of the development of
CKD, both in survivors of AKI and compared in populations
without AKI.
Thus, the goals of this systematic review and meta-analysis
were to estimate the risk for CKD, ESRD, death, and other
non-renal outcomes in persons with AKI vs. those without
AKI. We also sought to determine whether pre-existing renal
injury (decreased baseline glomerular filtration rate (GFR) or
pre-existing proteinuria) modified these associations.
RESULTS
We identified 618 citations meeting our search criteria. After
excluding 582 citations by reviewing their abstracts, 36
articles were selected for further review (Figure 1). Reasons
for exclusion are shown in Figure 1. Finally, 13 studies (from
14 articles)10–22 were selected for inclusion into the systematic
review. Study and patient characteristics from the selected
articles are listed in Table 1. Out of 13 studies, 11 followed up
more than 3000 patients and all were retrospective. One study
included patients with HIV exclusively12 and two studies
included hematopoietic stem cell transplant recipients.13,19
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The definitions of AKI varied substantially (Table 2).
Maximum length of follow-up ranged from 6 to 75 months.
All 13 studies sufficiently met the quality criteria.
Overall analyses
The renal outcomes for CKD and ESRD were calculated in
person-years. The pooled rate of CKD was 25.8 per 100
person-years (range 3.4–72.2) and ESRD was 8.6 per 100
person-years (range 0.63–28.1) (Table 2). The pooled
adjusted HR for CKD for AKI vs. no AKI was 8.8
(95% CI 3.1–25.5; Figure 2a) and for ESRD was 3.1 (95%
CI 1.9–5.0; Figure 2b). However, heterogeneity was very
high (I2475%). We were not able to reduce statistical
heterogeneity to below 75% with deletion of studies from the
pooled analyses.
Outcomes by severity of AKI
The outcomes of CKD and ESRD with varying degrees of
AKI were reported in 6 out of 13 studies. The risk for CKD
increased in a graded manner with mild AKI (adjusted HR
2.0, 95% confidence interval (CI) 1.4–2.8), moderate AKI
(adjusted HR 3.3, 95% CI 1.7–6.2), and severe AKI (adjusted
HR 28.2, 95% CI 21.1–37.5) (Table 3). The risk for ESRD also
increased in a graded manner with the severity of AKI: mild
AKI (adjusted HR 2.3, 95% CI 1.7–3.3), moderate AKI
(adjusted HR 5.0, 95% CI 2.6–9.8), and severe AKI (adjusted
HR 8.0, 95% CI 1.3–48.6). However, heterogeneity was still
high (I2450%) for all subgroup analyses, except for severe
AKI and risk for CKD. Thus, we removed studies one at a
time until heterogeneity fell below 25%. Statistical hetero-
geneity was reduced to 0% for the pooled analyses of
moderate and severe AKI and the outcome of CKD, and mild
and moderate AKI and the outcome of ESRD. In all cases in
which these more homogeneous estimates were created, the
point estimate did not differ significantly from the inclusive
analyses in any qualitative or quantitative manner (Supple-
mentary Table online).
Only one study stratified AKI by recovery status.12 Choi
et al.12 found that the adjusted risk for ESRD was not present
in those with mild AKI who recovered (adjusted HR 0.9, 95%
CI 0.6–1.4 vs. HR 2.2, 95% CI 1.5–3.1 in those without
recovery) and was markedly attenuated in those with
moderate–severe AKI who recovered (adjusted HR 2.5, 95%
CI 1.3–4.7 vs. HR 10.6, 95% CI 5.0–22.6 for those who did
not recover).
Effect modification by decreased baseline GFR and
pre-existing proteinuria before AKI
The presence of decreased baseline GFR modified the
relationship between AKI and both progressive CKD and
ESRD. In the two studies11,16 that reported the risk for CKD
after AKI in both those with and without decreased baseline
GFR, the relative risk for CKD was higher in patients without
decreased baseline GFR (adjusted HR 38.8, 95% CI
21.9–68.7) than in those with decreased baseline GFR
(adjusted HR 24.4, 95% CI 15.3–38.9). Similarly, in the three
Potentially relevant citations
screened for retrieval (n=618)
Studies retrieved for evaluation (n=36)
Studies included in systematic review (n=13)
Citations excluded (n=582)
Only AKI patients (n=6)
Review articles (n=4)
No outcome of interest (n=6)
Study population <50 (n=5)
Only mortality reported (n=2)
Figure 1 | Selection of studies.
Table 1 | Characteristics of included studies
First author, year
of publication Clinical setting
No of
patients
Years of
enrollment
Mean age
(in years)
Male
(%)
White
(%) CKD
CKD
progression ESRD Mortality
Hsu, 2009 Hospitalized 39,805 1996–2003 66.6 56.6 73 | |
Lo, 2009 Hospitalized 3773 1996–2003 63.5 61 66.6 | | |
Choi, 2010 HIV 17,325 1975–1995 44 98 28 | |
Weiss, 2006 HCT 174 2002 54 67 83 | |
Newsome, 2008 MI 87,094 1994–1995 77.1 51.5 87 | |
James (a), 2010a Coronary
angiography
11,249 2004 63.6 69.6 NR | | | |
Wald, 2009 ICU 8855 2006 62 60 NR | |
Lafrance, 2010 CKD 6862 2002 69.8 54 NR | |
Ando, 2010 HCT 158 1987 31 61.3 NR | |
James (b), 2010 Hospitalized and
non-hospitalized
920,985 2002 61 65 NR | | |
Ishani, 2009 Hospitalized 233,803 2000 79.2 38.8 89 | |
Amdur, 2009 Hospitalized 113,272 1999–2005 70.8 97.8 74 | | |
Ishani, 2011 Cardiac surgery 29,388 1999–2005 65.4 98.8 84.4 | | |
Abbreviations: CKD, chronic kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HCT, hematopoietic stem cell transplant; ICU, intensive care unit; MI,
myocardial infarction; NR, not reported.
CKD definition was variable in different studies—it was CKD stage 4 in Lo,11 Amdur,22 and decrease in GFR44ml/min/year in James (a),15 decrease in GFR of at least 25% from
baseline in Weiss.13
aData are ascertained from two different manuscripts that referred to the same study population.
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Table 2 | AKI definitions and outcomes
First author, year
of publication
AKI definition
severity
Method of
ascertainment
of AKI
Follow-up
(mean or
median in
months)
Post-discharge
mortality
overall (%)
Mortality rate
in AKI patients
(per 100 person-
years)a
Renal outcomes
in AKI patients
(per 100 person-years)a
CKD rate ESRD rate
Hsu, 2009 RRT Labs and code
for RRT
20.2 19.7 NR — NR
Lo, 2009 RRT Labs and code
for RRT
32.9 13.3 4.9 47.9 —
Choi, 2010 RIFLE Labs 68.4 48.5 9.9 — 0.6–5.6
Weiss, 2006 4 Twofold increase in Cr Labs 12 17.2 — 72.2 —
Newsome, 2008 Crm 0.3–0.5; 0.6–3.0 Labs 49.2 73.3 19.4 — 0.6
James (a), 2010 AKIN Labs 21.8 5.7 12.7–31.5 4.6–8.6a 1.6–4.2a
Wald, 2009 RRT Diagnostic
codes
36 34.8 10.1 — 2.6
Lafrance, 2010 k eGFR 25% and X5ml/min Labs 19.4 15.3 9.4 — 12.1
Ando, 2010 4Twofold increase in Cr Labs 73.8 4.1 —
James (b), 2010 ARF Diagnostic
codes
35 3 1.0–12.4a 0.03–15.8a —
Ishani, 2009 ARF Diagnostic
codes
24 64 28.8 — 2.5
Amdur, 2009 ARF and ATN Diagnostic
codes
75 44.7 7.8 22 —
Ishani, 2011 Class 1–4 Labs 61.2 23.1 4.1–6.6a 6.6–10.5a —
Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network Classification; ARF, acute renal failure; ATN, acute tubular necrosis; Cr, creatinine; eGFR, estimated
glomerular filtration rate; NR, not reported; RIFLE, Risk Injury Failure Loss End-Stage Renal Disease Classification; RRT, renal replacement therapy.
aRange of rates is provided for studies that examined outcomes by differing severity of AKI.
Ishani21—AKI definition (percent increase in creatinine postoperatively) for Class 1 (1%–24% rise in creatinine), Class 2 (25%–49%), Class 3 (50%–99%), and Class 4 (4100%).
Choi12—The rate of ESRD was 0.6 per 100 person-years for those with mild AKI and 5.6 per 100 person-years for those with moderate–severe AKI.
James (a)15—The rate of incident CKD was 4.6 per 100 person-years and ESRD was 1.6 per 100 person years for those with mild AKI, and 8.6 per 100 person-years and 4.2 per
100 person-years, respectively, for those with moderate–severe AKI. The mortality rate was 12.7 and 31.5 per 100 person-years, respectively, for those with mild AKI and with
moderate–severe AKI.
James (b)16—The rate of CKD progression was 0.03 per 100 person-years and mortality was 0.98 per 100 person-years for those with mild AKI, and it was 15.8 per 100 person-
years, and 12.4 per 100 person-years, respectively, for those with moderate–severe AKI.
Ishani 21—The rate of incident CKD was 6.6 per 100 person-years and mortality was 4.1 per 100 person-years for those with mild AKI, and 10.5 per 100 person-years and 6.6
per 100 person-years, respectively, for those with moderate–severe AKI.
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Figure 2 |Meta-analysis of chronic kidney disease (CKD) and end-stage renal disease (ESRD) associated with acute kidney injury
(AKI). (a) Pooled adjusted hazard ratios (HRs) for CKD after AKI. (b) Pooled adjusted HRs for ESRD after AKI.
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studies12,17,20 that reported the risk for ESRD in both those
with and without decreased baseline GFR, the relative risk for
ESRD was higher in those with AKI and without decreased
baseline GFR (adjusted HR 9.1, 95% CI 4.1–20.3) compared
with those with decreased baseline GFR (adjusted HR 1.9,
95% CI 1.6–20.3; Table 3).
Two studies compared the association of AKI with either
CKD12 or ESRD16 in patients with varying degrees of
underlying baseline proteinuria. Patients with AKI who had
pre-existing proteinuria (and normal baseline GFR) had
lower relative risk for CKD (defined as doubling of creatinine
or ESRD) (HR 9.7) compared with patients without any
proteinuria (HR 30.0, 95% CI 24.3–37).16 The modifying
effect of pre-existing proteinuria was less robust for the
outcome of ESRD alone (adjusted HR 3.7, 95% CI 2.4–5.7
with no proteinuria vs. adjusted HR 1.4, 95% CI 0.9–2.2 with
proteinuria;12 Table 3).
AKI and mortality
The overall post-discharge pooled mortality was 24.2%
(3–73.3%). The mortality rate in patients with AKI was
16.8 per 100 person-years (range 0.98–43.7). The adjusted
risk for death was 2.0 (95% CI 1.3–3.1) for those with AKI
compared with those without AKI (Figure 3). When we
eliminated the study by James et al.16 because of a very high
risk of death for AKI vs. no AKI, the pooled adjusted HR
became 1.6 (95% CI 1.3–2.1); however, this did not reduce
statistical heterogeneity.
AKI and non-renal outcomes
We also examined the association between AKI and non-
renal outcomes, when available (Supplementary Table
online). Mild AKI was associated with increased occurrence
of congestive heart failure in two studies (HR 1.4, 95% CI
1.1–1.7, I2¼ 10%) and risk of cardiovascular disease (HR 1.2,
Table 3 | Pooled HR for outcomes of CKD and ESRD by severity of AKI, decreased baseline GFR, and pre-AKI proteinuria
Grouping Comparison Outcome # Studies References HR 95% CI I2-value
Overall AKI vs. no AKI CKD 7 11,13,15,16,19,21,22 8.8 3–25.5 99%
AKI vs. no AKI ESRD 7 10,12,14,15,17,18,20 3.1 1.9–5.0 98%
Dose response Mild AKI vs. no AKI CKD 2 15,21 2.0 1.4–2.8 74%
Moderate AKI vs. no AKI 3 13,15,21 3.3 1.7–6.2 63%
Severe AKI vs. no AKI 2 11,13 28.2 21.1–37.5 0%
Mild AKI vs. no AKI ESRD 4 12,14,15,18 2.3 1.7–3.3 84%
Moderate AKI vs. no AKI 3 12,14,15 5.0 2.6–9.8 88%
Severe AKI vs. no AKI 2 12,17 8.0 1.3–48.6 98%
Effect modification by
decreased baseline GFR
AKI on decreased GFR vs. no AKI and
decreased GFR
CKD 2 11,16 24.4 15.3–38.9 89%
AKI on normal GFR vs. no AKI and
normal GFR
2 11,16 38.8 21.9–68.9 81%
AKI on decreased GFR vs. no AKI and
decreased GFR
ESRD 3 12,17,20 1.9 1.6–2.3 0%
AKI on normal GFR vs. no AKI and
normal GFR
3 12,17,20 9.2 4.1–20.3 93%
Effect modification by
pre-existing proteinuria
AKI with proteinuria vs. no AKI with
proteinuria
CKD 1 16 9.7 NA NA
AKI without proteinuria vs. no AKI
without proteinuria
1 16 30 24.3–37 NA
AKI with proteinuria vs. no AKI with
proteinuria
ESRD 1 12 1.4 0.9–2.2 NA
AKI without proteinuria vs. no AKI
without proteinuria
1 12 3.7 2.4–5.7 NA
Abbreviations: AKI, acute kidney injury; CI, confidence interval; CKD, chronic kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HR, hazards ratio;
NA, not available.
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Figure 3 |Pooled adjusted hazard ratios for mortality after acute kidney injury (AKI).
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95% CI 0.8–1.8, I2¼ 80%).12,23 Moderate–severe AKI was also
associated with an increased risk for congestive heart failure
and cardiovascular disease (HR 2.2, 95% CI 1.6–3.0 for
congestive heart failure, I2¼ 0%; HR 1.3, 95% CI 0.9–1.8,
I2¼ 0% for cardiovascular disease).12,15 In the only study that
reported these outcomes, AKI was associated with future
hospitalization for AKI (mild AKI HR 2.3, 95% CI 1.7–3.0
and moderate–severe AKI 5.1, 95% CI 3.4–7.6) but was not
associated with hospitalization for cerebrovascular accidents
(HR 1.2; 95% CI 0.43–3.2) or for other hospitalizations (HR
0.8, 95% CI 0.6–1.1).23
Meta-regression
We formally examined the relationship between five study-
level continuous variables and the risk for each of CKD and
ESRD via meta-regression. Although there was a trend toward
longer length of follow-up being associated with less risk for
CKD, and a higher proportion of females and older age being
associated with greater risk for ESRD, none of the study-level
variables were statistically associated with risk for the outcome.
DISCUSSION
This is the first systematic review and meta-analysis
summarizing the association of AKI with CKD and ESRD.
The data suggest that patients who survive AKI have a greater
risk for CKD, ESRD, and other adverse outcomes compared
with patients without AKI after adjustment for several
important confounding variables. The relationship between
AKI and CKD or ESRD was graded, with a greater risk
associated with increasing severity of AKI. The risk for ESRD
was modified by baseline GFR, and the risk for CKD was
modified by pre-existing proteinuria. Recovery of AKI
diminished the relationship between AKI and ESRD.
These findings that AKI increases the risk for both CKD
and ESRD are not surprising. However, this meta-analysis
provides an opportunity to systematically estimate the
associated absolute and relative risk of these outcomes after
AKI. One finding that is potentially counterintuitive is that
patients with normal GFR before AKI had a higher relative
risk for the development of ESRD compared with those with
AKI in the setting of decreased baseline GFR. For example, in
the study by Wald et al.,17 the absolute risk for ESRD without
AKI and decreased baseline GFR was 9.8% and increased to
18.4% for those with AKI and decreased baseline GFR
(approximately twofold higher). For those with normal
baseline GFR, the absolute risks for ESRD were 4.6% and
0.4% (more than 10-fold) for those with and without AKI,
respectively. Although the absolute risk for ESRD was lower
in those without decreased baseline GFR and AKI than in
those with AKI and decreased baseline GFR, the relative risk
(HR) for ESRD was greater in those with normal GFR
because of the extremely low probability (denominator) of
ESRD in those without AKI or decreased baseline GFR.
The reasons why AKI would increase the risk of CKD,
ESRD, and other adverse outcomes remain unknown. Data
from experimental animals suggests that AKI can induce
renal fibrosis, and also affect other organs in a deleterious
manner, such as the lungs, heart, and liver.4,5,24 Thus, despite
the fact that AKI is typically reversible in nature, on the basis
of serum creatinine concentrations there may be subclinical
renal and extra-renal damage that persists and mediates these
outcomes.
However, despite the fact that all studies conducted
multivariable adjustments to derive the adjusted point
estimates for the HRs via a substantial number of
demographic, physiological, and clinical variables, there still
remains the possibility that the ‘independent relationship’
between AKI and outcomes is still biased by residual
confounding because of unmeasured variables or imprecise
measurement of known confounders. For example, several
studies included in this systematic review11,14,16,17,20,22 used
ICD-9 codes for ascertainment of important confounders
such as CKD, diabetes, hypertension, and heart disease.
Administrative codes have been shown to under-report
comorbidities.25 Furthermore, claims provide nothing in
the context of the severity of the comorbidity (e.g., diet-
controlled type 2 diabetes vs. severe type 2 diabetes requiring
high doses of insulin with or without adequate glycemic
control). Thus, in the absence of a randomized, controlled
trial of an intervention that reduces AKI, which in turn
reduces the incidence of CKD, ESRD, or any other of the
outcomes potentially related to AKI, it is challenging to
deduce causality with absolute confidence.
The strengths of this systematic review are the
following: adequate length of follow-up in the studies (most
over 2 years); all studies reported parameter estimates of the
HR adjusted for confounders; four studies examined out-
comes associated with differing severities of AKI. The
limitations include a high degree of statistical heterogeneity
among the primary analyses, which may limit the validity of
the point estimates and confidence intervals. However,
we were able to demonstrate stable associations when
more homogeneous studies were pooled. Part of the
heterogeneity was related to different definitions of AKI
(and of CKD). However, the outcomes of ESRD and death
are less prone to bias.
As this review demonstrates an unequivocal association
between AKI and CKD in a number of large, well-conducted
studies, we would encourage the medical community to focus
efforts on determining whether this relationship is modifiable
or simply a prognostic factor that serves as a barometer and
predictor of ongoing and future risk. Only elegant studies in
experimental animals and randomized trials in humans of
interventions to prevent AKI before its occurrence or given
after AKI to ameliorate the severity and duration of injury or
to interfere with subsequent organ injury will be able to
address this question.
MATERIALS AND METHODS
This study was conducted in accordance with published guidelines
for systematic review, analysis, and reporting of meta-analyses of
observational studies.
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Studies eligible for review
A study published from January 1985 onward was eligible for
inclusion if it was conducted at least 6 months of follow-up of
patients after a defined episode of AKI, and if it reported the
incidence of at least one of the following outcomes: (1) ESRD, (2)
CKD, or (3) progression of CKD. We excluded studies that
contained fewer than 50 participants in the initial cohort and
studies that exclusively focused on ‘AKI syndromes’ (e.g., rapidly
progressive glomerulonephritis, hemolytic-uremic syndrome,
hepato-renal syndrome) and studies that reported only mortality.
Studies were required to include a control group without AKI.
Literature review and study selection
We searched the MEDLINE and EMBASE (January 1985 to
February 2011) databases using the following terms: acute renal
insufficiency, acute kidney injury, acute kidney failure, chronic
kidney disease, chronic renal failure, chronic renal insufficiency,
and ESRD; as well as progression (explode), treatment outcome, and
risk. An additional search was conducted through the Scopus,
and references of all selected articles were reviewed to identify any
eligible studies. The search was restricted to human subjects. Each
article chosen by the primary reviewer (SS) was reviewed by a
second reviewer to confirm eligibility (SGC).
Data Collection
Two reviewers (SS and SGC) extracted data using a standardized
data-extraction form. The reviewers extracted data on characteristics
of participants (number, age, and sex), clinical setting, type of study
(prospective vs. retrospective), dates of enrollment, definition and
severity of AKI, definition of CKD, and incidence of outcomes in
participants with and without AKI. Severity of AKI was grouped in
the ‘mild’, ‘moderate’, and ‘severe’, when possible. Mild AKI roughly
represented the equivalent of Stage 1 AKIN or RIFLE R AKI.
Moderate AKI roughly represented Stage 2 AKIN or RIFLE I AKI.
Severe AKI roughly represented AKIN Stage 3 or RIFLE F AKI or
dialysis-requiring AKI. Incident CKD was defined as per the study
investigators, representing stage 4 CKD in two studies,11,22 CKD
stage 3,19 doubling of creatinine or ESRD,16 and GFR decline
44 ml/min/year.15 Progressive CKD was defined as having pre-
existing decreased GFR (eGFRo60 ml/min) before AKI and meeting
the definition of stage 4 CKD 11 or doubling in creatinine/ESRD.16
Method quality was assessed by using criteria adapted from Hayden
et al.26 Any discrepancies about data extraction or quality score were
resolved by a third reviewer.
Outcome measures
Primary outcome measures were the adjusted HR for incident or
progressive CKD, and ESRD in survivors of AKI compared with
those without AKI. Progressive CKD was only evaluated in a
subgroup analysis of the two studies11,16 that reported this outcome
separately for those with and without decreased baseline GFR. The
adjusted HR for long-term mortality, cardiovascular events, and
hospitalizations were secondary outcomes. We also assessed
unadjusted incidence rates for each of these end points, defined
by the number of events in survivors beyond hospitalization or
other relevant short-term period (28 or 30 days) divided by patient-
years of follow-up. We assessed method quality of the studies by
using the criteria of Hayden et al.26: (1) representative study sample;
(2) lack of study attrition; (3) adequate measurement of prognostic
factor of interest (AKI); (4) adequate measurement of study
outcome; (5) accounted for important potential confounders; and
(6) utilization of appropriate statistical analyses.
Statistical analysis
A random effects meta-analysis was conducted to estimate the
magnitude of risk associated with AKI for each outcome, as
measured by the combined adjusted HRs with 95% CIs. Adjusted
risk estimates included those published in final multivariate models
for each study, which considered confounding from sociodemo-
graphic and clinical covariates, such as age, gender, race,
comorbidities, medications, and laboratory values. Inverse var-
iance-weighted averages of logarithmic HRs were calculated for each
of the endpoints. We formally assessed heterogeneity of effects
between studies with the Cochran Q and the I2 statistic.
We evaluated the association of AKI with the outcomes in the
following pre-specified subgroups: (1) dose response by severity of
AKI; (2) presence of decreased baseline GFR; and (3) presence of pre-
existing proteinuria. All pooled analyses were conducted using Review
Manager 5.0.25 (Cochrane Collaboration, Copenhagen). We also
performed meta-regression using SAS 9.1 (Cary, NC) on five study-
level variables (duration of follow-up, year of publication, overall
mortality rate, proportion of males, and mean age) to determine the
relationship between these variables expressed continuously and the
natural log of the relative risk of CKD and ESRD.
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